Streetbeat News

Analyst Ratings

CNFR

Piper Sandler analyst Paul Newsome has maintained an Underweight rating on Conifer Holdings (NASDAQ:CNFR) and reduced the price target from $1.07 to $0.61.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:26 pm

CNFR

Piper Sandler analyst Paul Newsome has maintained an Underweight rating on Conifer Holdings (NASDAQ:CNFR) and reduced the price target from $1.07 to $0.61.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:26 pm

ELAN

Piper Sandler analyst David Westenberg has maintained a Neutral rating on Elanco Animal Health (NYSE:ELAN) and increased the price target from $11 to $12 as reported on November 12, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:23 pm

ELAN

Piper Sandler analyst David Westenberg has maintained a Neutral rating on Elanco Animal Health (NYSE:ELAN) and increased the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:22 pm

OCX

Piper Sandler analyst David Westenberg has maintained a Neutral rating on OncoCyte (NASDAQ:OCX) and reduced the price target from $3.5 to $3.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:19 pm

NVTA

Piper Sandler analyst David Westenberg has maintained an Underweight rating on Invitae (NYSE:NVTA) and reduced the price target from $0.4 to $0.3.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:15 pm

ILMN

Piper Sandler analyst David Westenberg has maintained an Overweight rating on Illumina (NASDAQ:ILMN) but reduced the price target from $200 to $190.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:12 pm

AKYA

Piper Sandler analyst David Westenberg has maintained an Overweight rating on Akoya Biosciences (NASDAQ:AKYA) but reduced the price target from $11 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:09 pm

ADPT

Piper Sandler analyst David Westenberg has maintained an Overweight rating on Adaptive Biotechnologies (NASDAQ:ADPT) but reduced the price target from $13 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:08 pm

ANF

Abercrombie & Fitch (NYSE:ANF) received 8 analyst ratings in the last quarter, with an average price target of $56.0, which is below the current price of $66.8, suggesting a downside. The average price target has increased by 32.42% from the previous target of $42.29. The ratings were split evenly with 4 somewhat bullish and 4 indifferent, with no bullish or bearish ratings.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 9:01 pm